## DGX: Quest Diagnostics Incorporated - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -0.3% below STRENGTH zone (3.0-6.0%); PEG 1.46 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($171.91)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 5
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Quest Diagnostics Stock: Is DGX Outperforming the Healthcare Sector?**
- Source: Markets Financial Content | 20251215T080700 | Neutral | Relevance: 100%
- Quest Diagnostics (DGX) has seen mixed performance compared to the healthcare sector and competitors. While it lagged the State Street Health Care Select Sector SPDR ETF (XLV) over short and medium terms, DGX outperformed over the past 52 weeks. The company reported strong Q3 2025 results, exceeding analyst expectations for revenue and EPS, and raised its fiscal 2025 guidance.

**2. Quest Diagnostics Stock: Is DGX Outperforming the Healthcare Sector?**
- Source: Palmetto Grain Brokerage | 20251215T160802 | Neutral | Relevance: 99%
- Quest Diagnostics Incorporated (DGX) has seen mixed performance, with short-term underperformance compared to the State Street Health Care Select Sector SPDR ETF (XLV) but outperformance over the past 52 weeks. Despite reporting strong Q3 2025 results and raising guidance, the stock dropped intraday. Analysts are moderately bullish, with a "Moderate Buy" rating and an average price target indicating an 8.9% upside.

**3. Nonalcoholic Steatohepatitis Diagnostics Market Is Going to Boom |• Exact Sciences Corporation • Genfit SA**
- Source: openPR.com | 20251215T080932 | Somewhat-Bullish | Relevance: 81%
- Worldwide Market Reports (WMR) projects substantial growth for the Nonalcoholic Steatohepatitis Diagnostics Market, offering a comprehensive analysis of market dynamics, drivers, and regional insights. The report identifies key players such as Exact Sciences Corporation and Genfit SA and segments the market by types and applications. It provides actionable intelligence and forecasts using extensive primary and secondary research.

**4. Bio-Techne Stock: Is TECH Underperforming the Healthcare Sector?**
- Source: Barchart.com | 20251216T124258 | Somewhat-Bullish | Relevance: 73%
- Bio-Techne Corporation (TECH), a mid-cap life sciences company, has underperformed the Health Care Select Sector SPDR Fund (XLV) year-to-date and over the past 52 weeks, despite a recent three-month gain. The company's Q1 2026 revenue declined due to headwinds in cell therapy timing and biotech funding softness. Despite its recent struggles, analysts maintain a "Strong Buy" rating for TECH with a significant upside to its mean price target.

**5. Bio-Techne Stock: Is TECH Underperforming the Healthcare Sector?**
- Source: Markets Financial Content | 20251216T074000 | Somewhat-Bullish | Relevance: 61%
- Bio-Techne Corporation (TECH) has shown underperformance compared to the broader healthcare sector (XLV), with its stock decreasing almost 26% from its 52-week high. While it gained 13.7% in the past three months, it lagged XLV's 14% gain. The company's recent Q1 2026 revenue decline due to cell therapy timing and biotech funding softness contributed to investor concerns, despite analysts maintaining a "Strong Buy" rating.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 9 ($1.18M) |
| Sells | 8 ($8.86M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 52.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.8% (+0.1%)
- Blackrock Inc.: 9.0% (-3.0%)
- JPMORGAN CHASE & CO: 7.8% (+99.3%)
- Price (T.Rowe) Assoc: 6.3% (-2.6%)
- State Street Corpora: 4.7% (+0.8%)

### Key Risks

1. Insider selling cluster: $8.9M in recent transactions.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.46 suggests fair value with growth premium. Forward P/E 17.2x stretched relative to 6% growth. Insider selling cluster ($8.9M in 90 days), potential headwind. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $20.0B |
| Beta | 0.62 |
| 52W Range | $148.70 - $197.55 |
| Short Interest | 4.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.46 |
| Forward P/E | 17.2 |
| Current P/E | 18.2 |
| YoY Growth | 5.8% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -3.0% to -0.3% (+2.7% in 5 days), confirming momentum buildup. Below STRENGTH zone by 3.4pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.01x) but short-term weakness (below SMA20). MACD histogram bearish (-0.61), momentum weakening. RSI neutral at 40. OFD pattern: -F0N (Breakdown).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -0.35% (CS: 31) | Neutral |
| RSI_14 | 40.4 | Neutral |
| MACD Histogram | -0.61 | Bearish |
| vs SMA20 | 0.967x | Below |
| vs SMA50 | 0.974x | Below |
| vs SMA200 | 1.009x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $178.65
- **Stop Loss:** $171.91 (3.8% risk)
- **Target:** $185.39 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 148
- **Position Value:** $26,440.20
- **Portfolio %:** 26.44%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with balanced risk positioning. VIX remains calm at 16.48 while breadth shows modest improvement to 52%, indicating neither euphoria nor distress. Mixed sectoral themes from energy weakness to AI expansion suggest stock-picking environment rather than broad directional moves.*

### Earnings

**Next:** 2026-01-27 (Est: $2.36)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.50 | $2.60 | +3.9% |
| 2025Q2 | $2.57 | $2.62 | +1.9% |
| 2025Q1 | $2.15 | $2.21 | +2.8% |
| 2024Q4 | $2.18 | $2.23 | +2.1% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*